Biogen (NASDAQ:BIIB) Stock Rating Lowered by Wall Street Zen

Biogen (NASDAQ:BIIB) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other research analysts also recently issued research reports about the company. Evercore assumed coverage on Biogen in a research note on Friday, May 15th. They issued an “outperform” rating on the stock. The Goldman Sachs Group raised their price target on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. UBS Group lifted their price target on Biogen from $225.00 to $240.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen boosted their price target on Biogen from $215.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Mizuho dropped their price objective on Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $223.36.

Biogen Stock Performance

Shares of NASDAQ:BIIB opened at $202.95 on Friday. The firm has a fifty day moving average of $201.23 and a two-hundred day moving average of $190.64. The firm has a market capitalization of $29.99 billion, a P/E ratio of 35.92, a price-to-earnings-growth ratio of 6.20 and a beta of 0.17. Biogen has a 12-month low of $124.56 and a 12-month high of $219.72. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same period in the previous year, the company posted $5.47 EPS. Biogen’s revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts expect that Biogen will post 12.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Biogen

Several institutional investors have recently bought and sold shares of BIIB. Reflection Asset Management bought a new stake in shares of Biogen during the 4th quarter worth about $25,000. WPG Advisers LLC raised its stake in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares in the last quarter. First Horizon Corp acquired a new stake in Biogen in the 4th quarter worth approximately $30,000. WFA of San Diego LLC acquired a new stake in Biogen in the 2nd quarter worth approximately $32,000. Finally, Root Financial Partners LLC boosted its position in Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 123 shares during the period. 87.93% of the stock is currently owned by institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.